Clal Insurance’s Cellebrite CLBT Stock Holding History

Clal Insurance’s Portfolio CLBT Stock Details CLBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40.5M	Sell	2,773,014 -400,000	-13%	-$5.29M	0.18%	81
2026 Q1	$43.7M	Sell	3,173,014 -300,000	-9%	-$4.52M	0.26%	67
2025 Q4	$62.6M	Sell	3,473,014 -440,000	-11%	-$7.9M	0.4%	52
2025 Q3	$72.5M	Hold	3,913,014	–	–	0.55%	45
2025 Q2	$62.6M	Buy	3,913,014 +570,000	+17%	+$10.2M	0.62%	44
2025 Q1	$65M	Sell	3,343,014 -153,095	-4%	-$3.22M	0.67%	38
2024 Q4	$77M	Sell	3,496,109 -469,838	-12%	-$9.04M	0.69%	33
2024 Q3	$66.8M	Sell	3,965,947 -3,688,828	-48%	-$54.7M	0.59%	42
2024 Q2	$91.5M	Buy	7,654,775 +1,582,663	+26%	+$17.7M	0.96%	29
2024 Q1	$63M	Sell	6,072,112 -1,014,046	-14%	-$10.3M	0.71%	38
2023 Q4	$56.4M	Buy	7,086,158 +514,858	+8%	+$4M	0.74%	35
2023 Q3	$45.3M	Buy	+6,571,300	New	+$49.3M	0.63%	39

Other funds holding CLBT

TWCM

True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Clal Insurance's CLBT Position: Q2 2026 in Review

Clal Insurance reduced its Cellebrite (CLBT) stake by 13% in Q2 2026, selling an estimated $5.29M and leaving 2,773,014 shares worth $40.5M. The position accounts for 0.18% of the portfolio, ranked #81.

Clal Insurance first reported a position in CLBT in Q3 2023 and has held it in 12 quarters since. The position peaked at $91.5M in Q2 2024. 201 funds tracked by Wall St. Rank hold CLBT as of Q2 2026.

Clal Insurance held 2,773,014 shares of Cellebrite worth $40.5M as of Q2 2026.
Clal Insurance sold 400,000 Cellebrite shares in Q2 2026, an estimated $5.29M.
Cellebrite made up 0.18% of Clal Insurance's portfolio in Q2 2026, its #81 holding.
Clal Insurance first reported a position in Cellebrite in Q3 2023 and has held it in 12 quarters since.
Clal Insurance's Cellebrite position peaked at $91.5M in Q2 2024.
201 funds tracked by Wall St. Rank held Cellebrite as of Q2 2026.

Based on Clal Insurance's 13F filing for Q2 2026, filed 13 Aug 2026.